Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis
Open Access
- 27 October 2009
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 147 (4), 561-570
- https://doi.org/10.1111/j.1365-2141.2009.07872.x
Abstract
Data from the International Collaborative Gaucher Group Gaucher Registry were analysed to assess the relationship between enzyme replacement therapy with imiglucerase (ERT) and incidence of avascular necrosis (AVN) in type 1 Gaucher disease (GD1), and to determine whether the time interval between diagnosis and initiation of ERT influences the incidence rate of AVN. All patients with GD1 enrolled in the Gaucher Registry who received ERT and did not report AVN prior to starting therapy (n = 2700) were included. The incidence rate of AVN following initiation of ERT was determined. An incidence rate of AVN of 13·8 per 1000 person-years was observed in patients receiving ERT. Patients who initiated ERT within 2 years of diagnosis had an incidence rate of 8·1 per 1000 person-years; patients who started ERT ≥2 years after diagnosis had an incidence rate of 16·6 per 1000 person-years. The adjusted incidence rate ratio was 0·59 [95% confidence interval (CI) 0·36–0·96, P = 0·0343]. Splenectomy was an independent risk factor for AVN (adjusted incidence rate ratio 2·23, 95% CI 1·61–3·08, P < 0·0001). In conclusion, the risk of AVN was reduced among patients who initiated ERT within 2 years of diagnosis, compared to initiating treatment ≥2 years after diagnosis. A higher risk of AVN was observed among patients who had previously undergone splenectomy.Keywords
This publication has 31 references indexed in Scilit:
- The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patientsAmerican Journal of Hematology, 2009
- Management of non‐neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoringJournal of Inherited Metabolic Disease, 2008
- Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort studyClinical Genetics, 2008
- Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literatureAnnals of Hematology, 2008
- Increased plasma macrophage inflammatory protein (MIP)-1α and MIP-1β levels in type 1 Gaucher diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2007
- Effective cell and gene therapy in a murine model of Gaucher diseaseProceedings of the National Academy of Sciences, 2006
- Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patientsJournal of Inherited Metabolic Disease, 2006
- Haemorheology in Gaucher diseaseEuropean Journal of Haematology, 2005
- Individualization of long-term enzyme replacement therapy for Gaucher diseaseGenetics in Medicine, 2005
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991